Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 03, 2021

SELL
$76.02 - $100.5 $179,711 - $237,582
-2,364 Closed
0 $0
Q4 2020

Jan 13, 2021

BUY
$80.74 - $97.7 $4,359 - $5,275
54 Added 2.34%
2,364 $206,000
Q3 2020

Oct 14, 2020

BUY
$85.07 - $109.69 $935 - $1,206
11 Added 0.48%
2,310 $207,000
Q2 2020

Jul 16, 2020

BUY
$74.18 - $108.93 $170,539 - $250,430
2,299 New
2,299 $239,000
Q1 2020

Apr 17, 2020

SELL
$63.18 - $85.97 $174,250 - $237,105
-2,758 Closed
0 $0
Q4 2019

Jan 14, 2020

SELL
$73.04 - $95.72 $49,228 - $64,515
-674 Reduced 19.64%
2,758 $241,000
Q3 2019

Oct 24, 2019

BUY
$72.82 - $86.52 $14,272 - $16,957
196 Added 6.06%
3,432 $255,000
Q2 2019

Jul 15, 2019

BUY
$73.52 - $88.7 $237,910 - $287,033
3,236 New
3,236 $275,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Raymond James Trust N.A. Portfolio

Follow Raymond James Trust N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Trust N.A., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Trust N.A. with notifications on news.